Physician profile
Polin Lay
NPI 1699334201
$3,621.76
in general payments reported to CMS, 2019-2025
12 companies · $713 in 2025
The $713 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $206 · 2021: $437 · 2022: $577 · 2023: $740 · 2024: $579 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $632.27 | 2019-2025 | Precision 1, Precision7, Total30 |
| Bausch & Lomb Americas INC. | $501.87 | 2022-2025 | Xiidra, Miebo, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $495.51 | 2019-2021 | |
| Abbvie INC. | $492.26 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $352.26 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $328.71 | 2023-2024 | |
| Johnson & Johnson Vision Care, INC. | $256.73 | 2019-2025 | |
| Dompe US, INC. | $154.98 | 2024-2025 | Oxervate |
| Coopervision INC. | $150.86 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $142.39 | 2022-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $90.00 | 2019 | |
| Thea Pharma INC. | $23.92 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polin Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.